A Novel Paradigm for Adult‐Onset Type 1 Diabetes: Once‐Weekly Basal Insulin and SGLT‐2 Inhibition to Harness Residual β‐Cell Function
- 1Blizard Institute Queen Mary University of London London UK
- 2Università Campus Bio‐Medico Rome Italy
Abstract
Type 1 diabetes (T1D) in adults is characterised by a less aggressive disease course than in children. Most patients retain preserved C‐peptide (> 0.2 nmol/L) and some of them benefit from a protracted phase without the need for insulin. Here, we propose a hypothesis‐generating therapeutic paradigm with once‐weekly basal insulin combined with an SGLT2 inhibitor (SGLT2is) as initial therapy in T1D patients with preserved C‐peptide. Once‐weekly basal insulin, approved in Europe and now also in the US, confirm comparable HbA1c reductions to insulin degludec or glargine, albeit always alongside prandial insulin. SGLT2is, approved as adjuncts in T1D in select regions, can control prandial peaks without boluses. No trials have tested the combination of weekly insulin with SGLT2is in adult T1D patients. Nonetheless, the rationale is robust especially in adults with C‐peptide > 0·2 nmol/L. In this respect, we urge proof‐of‐concept trials of 12‐months randomised studies in adults ≥ 18 years, to evaluate this combination.
Related
- Endurance Training Improves Insulin Sensitivity, Metabolic Flexibility, and Mitochondrial Function in Type 2 Diabetes.
- Combined residual inflammation and anemia in relation to kidney function among adults with diabetes: a CHARLS-based cross-sectional and longitudinal study
- Changes in ectopic lipids, insulin sensitivity, and beta cell function after a low-fat vegan diet in adults with type 2 diabetes: a 16-week single-arm clinical trial.
- Adipo-B Index as a Novel Predictor of Beta-Cell Secretory Function Without Measuring Insulin: Cross-Therapeutic Validation Against C-Peptide Index in Treatment-Naive Type 2 Diabetes
- Concentrated growth factor in combination with insulin for improving type 2 diabetes mellitus alveolar bone regeneration: a pilot study
BibTeX
@article{pozzilli2026novel,
title = {{A Novel Paradigm for Adult‐Onset Type 1 Diabetes: Once‐Weekly Basal Insulin and SGLT‐2 Inhibition to Harness Residual β‐Cell Function}},
author = {Paolo Pozzilli and Richard David Leslie},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2026},
month = oct,
doi = {10.1002/dmrr.70247},
url = {https://doi.org/10.1002/dmrr.70247},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A Novel Paradigm for Adult‐Onset Type 1 Diabetes: Once‐Weekly Basal Insulin and SGLT‐2 Inhibition to Harness Residual β‐Cell Function
AU - Paolo Pozzilli
AU - Richard David Leslie
PY - 2026
DA - 2026/10/27
JO - Diabetes/Metabolism Research and Reviews
DO - 10.1002/dmrr.70247
UR - https://doi.org/10.1002/dmrr.70247
AB - Type 1 diabetes (T1D) in adults is characterised by a less aggressive disease course than in children. Most patients retain preserved C‐peptide (> 0.2 nmol/L) and some of them benefit from a protracted phase without the need for insulin. Here, we propose a hypothesis‐generating therapeutic paradigm with once‐weekly basal insulin combined with an SGLT2 inhibitor (SGLT2is) as initial therapy in T1D patients with preserved C‐peptide. Once‐weekly basal insulin, approved in Europe and now also in the US, confirm comparable HbA1c reductions to insulin degludec or glargine, albeit always alongside prandial insulin. SGLT2is, approved as adjuncts in T1D in select regions, can control prandial peaks without boluses. No trials have tested the combination of weekly insulin with SGLT2is in adult T1D patients. Nonetheless, the rationale is robust especially in adults with C‐peptide > 0·2 nmol/L. In this respect, we urge proof‐of‐concept trials of 12‐months randomised studies in adults ≥ 18 years, to evaluate this combination.
SN - 1520-7552
SN - 1520-7560
ER -